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subsequent decisions by FJC.METHODS:We examined all IQWiG assessments and
corresponding FJC decisions up to 01.06.2012 regarding possible disagreements.
Afterwards we categorized these findings and tried to identify schemes where FJC
regularly deviates from IQWiG’s recommendations. We excluded decisions on Or-
phan drugs because of the special regulations for these drugs. RESULTS: Totally 13
newly launched products were evaluated by IQWiG with subsequent decision on
additional benefit by the FJC. An additional benefit is not proven for more than 70%
of patient groups. The extent of the additional benefit doesn’t differ between as-
sessment and decision in 8 products. The FJC merges patient populations being
separately analyzed by IQWiG in 4 drugs. In case of Eribulin the result of IQWiG
assessment is no additional benefit in both subgroups whereas the FJC decides on
a slight and smaller benefit in the subgroups. Deviations in number of patients and
costs can’t be assessed, because IQWiG doesn’t always provide information on
these. CONCLUSIONS: Besides one case there are minor differences between as-
sessments and subsequent decisions. The impact of these differences on the price
negotiations is unknown until now.
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OBJECTIVES: The Act on the Reform of the Market for Medicinal Products (AMNOG)
funds, effective since 01.01.2011, implemented an early benefit assessment of
drugs after launch in Germany. This assessment is based on a dossier submitted by
the manufacturer for which the Federal Joint Committee (FJC) provides a detailed
template. The objective is to investigate the challenges within a pharmaceutical
company occurring during the preparation of a dossier. METHODS: First, the tem-
plate of FJC is analyzed to identify the data and skills needed to fulfill the require-
ments. These requirements are then linked to specialized departments within the
company. Finally, governance principles are developed. RESULTS: Data regarding
drug and disease, available treatments and guidelines, clinical study program as
well as German epidemiology and cost are needed for the dossier. Consequently,
profound skills in medicine, evidence-based medicine and biometrics are neces-
sary to support medical writing of the dossier. The departments Medical, Health
Economics & Outcomes Research (HEOR), Market Access, Regulatory, Commercial
and Legal are crucial for the development of a successful dossier. To finalize the
dossier in time, two teams are defined: One operational team with delegates from
Medical, HEOR and Regulatory prepares the dossier according to the FJC-require-
ments with or without support by an external vendor. Strategic decisions including
aspects not confined to the individual product are taken by the cross-functional
governance board. Beyond this a close alignment with global and regional Access
policies is essential. CONCLUSIONS: The preparation of a benefit dossier requires a
new area of cooperation at the local level within pharmaceutical companies involv-
ing a cross-functional team. Of particular importance are the HEOR and Regulatory
departments where essential information and expertise reside, putting these team
in the spotlight.
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OBJECTIVES: To assess the effort it takes for manufacturers to develop HTA sub-
missions in Germany and the UK and to compare it to the estimates proposed by
the legislator. METHODS: A review on available sources was conducted to assess
the proposed as well as the actual effort it takes to develop and submit a dossier to
the HTA agencies in Germany (G-BA/ IQWiG) and UK (NICE). Evidence from the
review was supplemented by interviews with experts from pharmaceutical and
consulting industry. RESULTS: The time proposed for HTA submission was partic-
ular low in Germany were the legislator estimated that a submission to the G-BA/
IQWiG could be done within 2.5 days. However, according to the review and expert
judgment actual effort of HTA submission in Germany required a minimum of one
year for multidisciplinary teams collaborating on generation of evidence following
the exact guidance that details the methods, contents, and format of submissions
to the German HTA body. Effort in UK is seen as lower due to the more collaborative
and interactive nature of the process avoiding unnecessary effort and allowing for
a clear focus on the critical questions. However, since the process in Germany is
still fairly new, it could be assumed that due to learning curve effort will be lower in
subsequent submission as the process gets more rationalized. CONCLUSIONS: The
actual burden exceeds the burden that was estimated particularly in Germany by
magnitudes. This study shows that the burden also depends on the organization of
the consulting process during dossier development. Whereas the early and struc-
tured interaction in UK was seen as favorable to avoid spending time on aspects
that are not relevant for the decision of the HTA body the highly formalized Ger-
man process where such an action is much less intense requires a more mecha-
nistic approach.
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OBJECTIVES: Since 2004 the National Institute of Health and Clinical Excellence
requires manufacturers to conduct a probabilistic sensitivity analysis for their
technology appraisals. The objective of this review is to assess the outcomes of
different probabilities of being cost effective and compare this with the actual
decision making done by NICE.METHODS: The search term “probabilistic sensitiv-
ity analysis” was used on NICE homepage (2012-01-25). The chapters included in
the search was assessed and included for further review if a probability of being
cost effective was provided regardless of what threshold was mentioned. If several
probabilities were provided the number provided by the evidence review group
were used rather than those provided by the manufacturer since these numbers
are more likely to be used in the decision making. If several scenarios were pre-
sented the base case scenario was chosen. Finally the probabilities of being cost
effective versus was compared with the actual decision making which could result
in 2 outcomes either it was recommended or not recommended. The results were
plotted into a graph to illustrate the relationship between PSA outcomes versus
final recommendation. The assessments were ranked according to their probabil-
ity of being cost effective. RESULTS: Thirty-one assessments were included for
final review. A higher probability of a technology being cost effective correlated to
more positive decision making and there even is observed a clear threshold where
technologies with a 40% certainty of being cost effective tend to be recommended
(3 out of 20) whereas those below are not recommended (2 out of 11) irrespective of
ICER. CONCLUSIONS: Reports suggested that ICER estimate was not a robust driver
of decision making. NICE applicant should provide an increase attention to PSA on
the top of ICER estimate.
PHP161
INTEGRATION OF VALUE OF INFORMATION INTO THE DECISION MAKING
PROCESS IN IRELAND
McCullagh LM1, Walsh C2, Barry M3
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2Trinity College Dublin, Dublin,
Ireland, 3St. James’s Hospital, Dublin, Ireland, Ireland
In Ireland, the National Centre for Pharmacoeconomics (NCPE) appraises the cost
effectiveness of technologies in response to requests from the Health Service Ex-
ecutive (HSE). A large number of reimbursement decisions are based upon the
appraisal of company Health Technology Assessments (HTAs). HTAs are con-
ducted in accordance with existing agreed Irish HTA Guidelines. These guidelines
do not specify the requirement of Expected Value of Perfect Information (EVPI)
analysis. OBJECTIVES: To examine the application of EVPI analysis as part of the
formal HTA process. METHODS: There is no set cost-effectiveness threshold in
Ireland; however, technologies with ICERs  €20,000/QALY are less likely to be
reimbursed. This threshold was considered here. EVPI estimates (at €20,000/QALY)
were determined directly from the PSA results of company economic models. Es-
timates were scaled up to 10 year population EVPI (PEVPI) levels. NCPE recommen-
dations on reimbursement were recorded. RESULTS: The NCPE have estimated
PEVPI values on nine company economic evaluations to date. All evaluations were
for newly licensed technologies; eight were pharmaceuticals and one was a diag-
nostic. Two technologies had ICERs €120,000 with PEVPI estimates €20 million;
reimbursement was not recommended. Two technologies dominated the relevant
comparators and one had an ICER €10,000/QALY. All PEVPI values were below €1
million. Reimbursement of all three technologies was recommended. The four
remaining technologies had ICERs in the range of €21,000/QALY -€30,000/QALY;
their PEVPI values ranged from about €1.5 million - €35 million. Reimbursement
was not recommended. In two cases (original PEVPI values of €2.4 million and €35
million respectively) the manufacturer subsequently revised the price. Reimburse-
ment was then recommended. There was no formal reanalysis of PEVPI.
CONCLUSIONS: To date, the formal analysis of PEVPI has not affected the decision
to accept or reject technologies with ICERs lower and higher than €20,000/QALY
respectively.
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OBJECTIVES: To illustrate how decision-making in England and Wales is influ-
enced by cost effectiveness and other factors, with particular emphasis on deci-
sions for end-of-life treatments. METHODS: An analysis of all technology apprais-
als published by the National Institute for Health and Clinical Excellence (NICE)
from 1st March 2000 to 31st May 2012 was conducted, with recommendations
categorised as ‘recommended’, ‘optimised, ‘not recommended’, ‘only in research’
and ‘non-submission’, by therapeutic area and by technology process (multiple
technology appraisal or single technology appraisal). These categories were then
mapped against the most plausible cost per QALY estimate and the recommenda-
tions were contextualised with the factors used in decision-making. RESULTS:
Since March 2000, NICE has published 256 appraisals containing 482 individual
recommendations on the use of technologies in England and Wales. The majority
(78%) of these decisions recommended the use of a technology either in line with its
licensed indication (‘recommended’) or under specific conditions (‘optimised’).
‘Only in research’ and ‘not recommended’ decisions represented 5% and 14% of all
recommendations respectively. Of the 135 recommendations in technology ap-
praisals which considered the use of oncology treatments, 61% were ‘recom-
mended’ or ‘optimised’. Since January 2009, 15 end-of-life technologies have been
considered of which 9 were recommended because the additional weight that
needed to be assigned to the QALY benefits was acceptable to justify these as an
appropriate use of NHS resources. Examples from other therapeutic areas show
how factors other than cost effectiveness have affected the recommendations,
such as equality considerations, or the impact of health-related benefits not cap-
tured in the QALY. CONCLUSIONS: NICE has provided guidance on a wide range of
new and established technologies, with the majority recommended for use. The
starting point for the decisions is the ICER in line with NICE’s commitment to
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